662 related articles for article (PubMed ID: 31696664)
21. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
22. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in Cell Membrane-Derived Biomimetic Nanotechnology for Cancer Immunotherapy.
Raza F; Zafar H; Zhang S; Kamal Z; Su J; Yuan WE; Mingfeng Q
Adv Healthc Mater; 2021 Mar; 10(6):e2002081. PubMed ID: 33586322
[TBL] [Abstract][Full Text] [Related]
24. Cell surface-nanoengineering for cancer targeting immunoregulation and precise immunotherapy.
Wang Y; Huang G; Hou Q; Pan H; Cai L
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(4):e1875. PubMed ID: 36567668
[TBL] [Abstract][Full Text] [Related]
25. Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors.
Qi J; Jin F; Xu X; Du Y
Int J Nanomedicine; 2021; 16():1435-1456. PubMed ID: 33654395
[TBL] [Abstract][Full Text] [Related]
26. Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors.
Cho H; Kim K
Expert Opin Drug Deliv; 2024 Apr; 21(4):627-638. PubMed ID: 38682272
[TBL] [Abstract][Full Text] [Related]
27. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
[TBL] [Abstract][Full Text] [Related]
28. Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy.
Saeed M; Gao J; Shi Y; Lammers T; Yu H
Theranostics; 2019; 9(26):7981-8000. PubMed ID: 31754376
[TBL] [Abstract][Full Text] [Related]
29. Nanovaccines for cancer immunotherapy.
Zhang Y; Lin S; Wang XY; Zhu G
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Sep; 11(5):e1559. PubMed ID: 31172659
[TBL] [Abstract][Full Text] [Related]
30. Non-viral gene delivery for cancer immunotherapy.
Wang W; Saeed M; Zhou Y; Yang L; Wang D; Yu H
J Gene Med; 2019 Jul; 21(7):e3092. PubMed ID: 30991453
[TBL] [Abstract][Full Text] [Related]
31. Nanomedicine as a multimodal therapeutic paradigm against cancer: on the way forward in advancing precision therapy.
Sandbhor P; Palkar P; Bhat S; John G; Goda JS
Nanoscale; 2024 Mar; 16(13):6330-6364. PubMed ID: 38470224
[TBL] [Abstract][Full Text] [Related]
32. Nanomedicine-mediated optimization of immunotherapeutic approaches in cervical cancer.
Venkatas J; Singh M
Nanomedicine (Lond); 2021 Jun; 16(15):1311-1328. PubMed ID: 34027672
[TBL] [Abstract][Full Text] [Related]
33. Targeted Nanoparticle Drug Delivery System for the Enhancement of Cancer Immunotherapy.
Zhang H; Wu Y; Hu Y; Li X; Zhao M; Lv Z
J Biomed Nanotechnol; 2019 Sep; 15(9):1839-1866. PubMed ID: 31387674
[TBL] [Abstract][Full Text] [Related]
34. Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Sau S; Alsaab HO; Bhise K; Alzhrani R; Nabil G; Iyer AK
J Control Release; 2018 Mar; 274():24-34. PubMed ID: 29391232
[TBL] [Abstract][Full Text] [Related]
35. Multifunctional nanoparticles for cancer immunotherapy.
Saleh T; Shojaosadati SA
Hum Vaccin Immunother; 2016 Jul; 12(7):1863-75. PubMed ID: 26901287
[TBL] [Abstract][Full Text] [Related]
36. Nanoparticles: Properties and Applications in Cancer Immunotherapy.
Iscaro A; Howard NF; Muthana M
Curr Pharm Des; 2019; 25(17):1962-1979. PubMed ID: 31566122
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticle-based immunotherapy for cancer.
Shao K; Singha S; Clemente-Casares X; Tsai S; Yang Y; Santamaria P
ACS Nano; 2015 Jan; 9(1):16-30. PubMed ID: 25469470
[TBL] [Abstract][Full Text] [Related]
38. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects.
Chen J; Cong X
Biomed Pharmacother; 2023 Jan; 157():113998. PubMed ID: 36399829
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
[TBL] [Abstract][Full Text] [Related]
40. Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small.
Tyagi P; Subramony JA
J Control Release; 2018 Feb; 272():159-168. PubMed ID: 29355619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
